Abstract
The CNS is both source and target of melatonin. It is released from the pineal to the circulation and, in elevated concentrations, into the third ventricle. Levels by 3 orders of magnitude higher than in the circulation have been found in the CNS. The mammalian circadian pacemaker, suprachiasmatic nucleus (SCN), controls the pineal, but is also major subject to feedback information on darkness, transduced by two G-protein coupled melatonin receptors, MT1 and MT2, which cause suppression of neuronal firing and circadian phase resetting. Two MT1 and MT2 agonists, ramelteon and agomelatine, display sleep-promoting properties. Agomelatine additionally inhibits 5-HT2C receptors, the basis of an antidepressant effect. Melatonin, ramelteon and agomelatine have been tested in clinical trials. Only ramelteon has received approval by the FDA, as a sleeping pill. Bioactive melatonin analogs, N-acetylserotonin, 5-methoxytryptamine, N,Ndimethyl- 5-methoxytryptamine, and 5-methoxytryptophol are produced in the CNS. Interplays between these compounds, including the serotoninergic system, are likely. N-Acetylserotonin is abundant in hippocampus, cerebellum, midbrain, pons and medulla. Neuroprotective actions of melatonin include antiamyloidogenic, antiexcitatory/antiexcitotoxic, antioxidant effects and modulation of mitochondrial metabolism, with consequences for radical formation and aging. The remarkable pleiotropy of melatonin includes other binding sites, such as calmodulin, calreticulin and a nuclear calreticulin homolog, members of the ROR/RZR family, quinone reductase 2 and specific mitochondrial sites. N1-acetyl-N2-formyl-5- methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK) are major melatonin metabolites in the CNS and also display biological activities. For instance, AMK inhibits neuronal NO synthase already at 10-11 M, and modulates mitochondrial metabolism. By interacting with NO, AMK forms 3-acetamidomethyl-6-methoxycinnolinone (AMMC).
Keywords: Agomelatine, N1-acetyl-N2-formyl-5-methoxykynuramine, N1-acetyl-5-methoxykynuramine, N-acetylserotonin, melatonin, 5-methoxyindoles, ramelteon, serotonin
Central Nervous System Agents in Medicinal Chemistry
Title: Actions of Melatonin, Its Structural and Functional Analogs in the Central Nervous System and the Significance of Metabolism
Volume: 7 Issue: 4
Author(s): Rudiger Hardeland and Burkhard Poeggeler
Affiliation:
Keywords: Agomelatine, N1-acetyl-N2-formyl-5-methoxykynuramine, N1-acetyl-5-methoxykynuramine, N-acetylserotonin, melatonin, 5-methoxyindoles, ramelteon, serotonin
Abstract: The CNS is both source and target of melatonin. It is released from the pineal to the circulation and, in elevated concentrations, into the third ventricle. Levels by 3 orders of magnitude higher than in the circulation have been found in the CNS. The mammalian circadian pacemaker, suprachiasmatic nucleus (SCN), controls the pineal, but is also major subject to feedback information on darkness, transduced by two G-protein coupled melatonin receptors, MT1 and MT2, which cause suppression of neuronal firing and circadian phase resetting. Two MT1 and MT2 agonists, ramelteon and agomelatine, display sleep-promoting properties. Agomelatine additionally inhibits 5-HT2C receptors, the basis of an antidepressant effect. Melatonin, ramelteon and agomelatine have been tested in clinical trials. Only ramelteon has received approval by the FDA, as a sleeping pill. Bioactive melatonin analogs, N-acetylserotonin, 5-methoxytryptamine, N,Ndimethyl- 5-methoxytryptamine, and 5-methoxytryptophol are produced in the CNS. Interplays between these compounds, including the serotoninergic system, are likely. N-Acetylserotonin is abundant in hippocampus, cerebellum, midbrain, pons and medulla. Neuroprotective actions of melatonin include antiamyloidogenic, antiexcitatory/antiexcitotoxic, antioxidant effects and modulation of mitochondrial metabolism, with consequences for radical formation and aging. The remarkable pleiotropy of melatonin includes other binding sites, such as calmodulin, calreticulin and a nuclear calreticulin homolog, members of the ROR/RZR family, quinone reductase 2 and specific mitochondrial sites. N1-acetyl-N2-formyl-5- methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK) are major melatonin metabolites in the CNS and also display biological activities. For instance, AMK inhibits neuronal NO synthase already at 10-11 M, and modulates mitochondrial metabolism. By interacting with NO, AMK forms 3-acetamidomethyl-6-methoxycinnolinone (AMMC).
Export Options
About this article
Cite this article as:
Hardeland Rudiger and Poeggeler Burkhard, Actions of Melatonin, Its Structural and Functional Analogs in the Central Nervous System and the Significance of Metabolism, Central Nervous System Agents in Medicinal Chemistry 2007; 7 (4) . https://dx.doi.org/10.2174/187152407783220823
DOI https://dx.doi.org/10.2174/187152407783220823 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and SARs of Coumarin Fused 1,5-Benzothiazepines as Novel Anticancer and Antioxidant Agents
Mini-Reviews in Organic Chemistry Melatonin and Melatonin Agonists as Adjunctive Treatments in Bipolar Disorders
Current Pharmaceutical Design Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry Statins and Protein Prenylation in Cancer Cell Biology and Therapy
Anti-Cancer Agents in Medicinal Chemistry Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology The Role of Integrins in Glioma Biology and Anti-Glioma Therapies
Current Pharmaceutical Design In Vitro Blood-Brain Barrier Models – Latest Advances and Therapeutic Applications in a Chronological Perspective
Mini-Reviews in Medicinal Chemistry SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines
Recent Patents on Biotechnology Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges
Current Pharmaceutical Biotechnology Magnetic Nanoparticles for MRI of Brain Tumors
Current Pharmaceutical Biotechnology Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology Multiple Roles of Annexin A2 in Post-Transcriptional Regulation of Gene Expressio
Current Protein & Peptide Science Nongenomic Actions of Thyroid Hormones: Every why has a Wherefore
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy Perfusion MRI of Brain Neoplams
Current Medical Imaging Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Targeted Radiotherapy for Malignant Gliomas
Current Drug Discovery Technologies Targeting of Metabotropic Glutamate Receptors for the Treatment of Schizophrenia
Current Pharmaceutical Design